Key Points: LMO2 is deacetylated by the NAMPT/SIRT2 pathway. LMO2 deacetylation is essential for LIM domain binding 1 binding and TAL1 complex activation during hematopoiesis and T-ALL leukemogenesis.
Nonresolving inflammation, a hallmark of underlying severe inflammatory processes such as sepsis, acute respiratory distress syndrome and multiple organ failure is a major cause of admission to the intensive care unit and high mortality rates. Many survivors develop new functional limitations and health problems, and in cases of sepsis, approximately 40% of patients are rehospitalized within three months. Over the last few decades, better treatment approaches have been adopted. Nevertheless, the lack of knowledge underlying the complex pathophysiology of the inflammatory response organized by numerous mediators and the induction of complex networks impede curative therapy. Thus, increasing evidence indicates that resolution of an acute inflammatory response, considered an active process, is the ideal outcome that leads to tissue restoration and organ function. Many mediators have been identified as immunoresolvents, but only a few have been shown to contribute to both the initial and resolution phases of severe systemic inflammation, and these agents might finally substantially impact the therapeutic approach to severe inflammatory processes. In this review, we depict different resolution mediators/immunoresolvents contributing to resolution programmes specifically related to life-threatening severe inflammatory processes.
Acute myeloid leukemia (AML) remains a therapeutic challenge despite recent therapeutic advances. Although monoclonal antibodies (mAbs) engaging natural killer (NK) cells via antibody-dependent cellular cytotoxicity (ADCC) hold promise in cancer therapy, almost none have received clinical approval for AML, so far. Recently, CD276 (B7-H3) has emerged as a promising target for AML immunotherapy, due to its high expression on leukemic blasts of AML patients. Here, we present the preclinical development of the Fc-optimized CD276 mAb 8H8_SDIE with enhanced CD16 affinity. We demonstrate that 8H8_SDIE specifically binds to CD276 on AML cell lines and primary AML cells and induces pronounced NK cell activation and degranulation as measured by CD69, CD25, and CD107a. Secretion of IFNγ, TNF, granzyme B, granulysin, and perforin, which mediate NK cell effector functions, was induced by 8H8_SDIE. A pronounced target cell-restricted lysis of AML cell lines and primary AML cells was observed in cytotoxicity assays using 8H8_SDIE. Finally, xenograft models with 8H8_SDIE did not cause off-target immune activation and effectively inhibited leukemia growth in vivo. We here present a novel attractive immunotherapeutic compound that potently induces anti-leukemic NK cell reactivity in vitro and in vivo as treatment option for AML.
Despite recent advances in immunophenotyping, the prognosis of acute myeloid leukemia (AML) is still mainly estimated using age and genetic markers. As the genetic heterogeneity of AML patients is high, flow cytometry-based classification with appropriate biomarkers can efficiently complement risk stratification and treatment selection. An increased expression of B7-H3 (CD276), an immune checkpoint protein, has been reported and associated with poor prognosis. However, the available data are limited and heterogeneous. Here, we used a novel, proprietary murine anti-B7-H3 8H8 antibody for the flow cytometric analysis of B7-H3 expression in AML blasts from 77 patients. Our antibody reliably detected substantial B7-H3 expression in 62.3% of AML patients. B7-H3 expression was higher in the monocytic French–American–British (FAB) M5 group and in intermediate and poor risk patients according to the European Leukemia Network. Using receiver operating characteristics (ROCs), we identified a specific fluorescence intensity cut-off of 4.45 to discriminate between B7-H3high and B7-H3low expression. High B7-H3 expression was associated with shorter overall survival (OS) and progression-free survival (PFS). In conclusion, we have developed a novel B7-H3 antibody that serves as a new tool for the detection of B7-H3 expression in AML and may help to facilitate risk stratification and treatment selection in AML patients.
Background Acute myeloid leukemia (AML) is the most frequent acute leukemia in adults. Although treatment options of AML have improved during the last decade, so far, no anti-tumor antibodies are clinically approved for AML therapy. The crucially important factor for the therapeutic success of monoclonal antibodies (mAbs) in cancer treatment is their ability to mediate antibody-dependent cellular cytotoxicity (ADCC) through natural killer (NK) cells. Recently, the coreceptor of immune-checkpoint B7 family B7-H3 (CD276) has emerged as a promising target for AML immunotherapy, due to its profound expression on leukemic blasts of AML patients. Methods Here we provide preclinical characterization of our previously developed B7-H3 mAb 8H8 in AML. By introduction of amino acid substitutions (S239D/I332E) in the Fc part, 8H8-SDIE provides enhanced affinity to the activating Fc receptor CD16 on NK cells. We characterized B7-H3 expression and binding of 8H8 on AML cell lines (n=12) and patient samples (n=64) and employed 8H8-SDIE in various in vitro assays. Results Flow cytometric analyses showed that 8H8-SDIE bound specifically to the target antigen at saturating doses of approximately 1 µg/mL on primary AML patients’ samples. Co-cultures of allogeneic peripheral blood mononuclear cells (PBMC) with B7-H3-positive primary AML cells, revealed that B7-H3-SDIE induced significant NK cell activation measured by CD69 and CD25 expression. In line, determination of CD107a upregulation confirmed significant induction of NK cell degranulation by our construct. Additional analysis of the supernatants by LegendPlex showed 8H8-SDIE treatment-induced secretion of immunomodulatory IFNγ and TNF as well es enhanced levels of Granzyme B, Granulysin, and Perforin mediating NK cell effector functions. No effects were observed in the presence of the corresponding iso-SDIE control. Target cell-restricted lysis of AML cell lines and primary AML patients’ samples by 8H8-SDIE was potently induced in Europium and FACS-based cytotoxicity assays, while iso-SDIE treatment did not induce lysis of leukemic cells. Conclusions Taken together, we here introduce a novel attractive immunotherapeutic compound potently inducing NK cell anti-leukemic reactivity as a beneficial treatment option for AML.
Background The activating immunoreceptor NKG2D is expressed on cytotoxic lymphocytes (CTL) like NK cells, CD8+ cytotoxic T cells and γδ T cells. It potently stimulates CTL effector functions upon recognition of its ligands (NKG2DL) that are generally absent on healthy tissue, but induced by cellular stress including malignant transformation. Recent studies demonstrated that – somewhat surprisingly - also the NKG2D receptor can be expressed on tumor cells of various origins and may affect cellular functions of the malignant cells like tumor growth and metastasis. Here we report on the role of NKG2D expression in acute myeloid leukemia (AML). Methods Expression of NKG2D on the cell surface of patient AML cells and its correlation with differentiation/maturation as well as stemness characteristics depending on NKG2D expression were studied. Furthermore, the functional role of NKG2D in AML cells on signaling and stem cell properties was investigated. Results Primary leukemic cells of AML patients expressed substantial levels of NKG2D on the cell surface in approximately 40% of 156 investigated patients. Within the patient cohort, expression of NKG2D was associated with more differentiated subtypes of AML according to the FAB classification. Notably, within the leukemic cell population of individual patients, NKG2D expression significantly correlated with CD34 negativity. In line, after sorting bulk AML cells of patients according to NKG2D expression, only the subpopulation lacking NKG2D expression showed stemness characteristics like the ability to give rise to colonies in colony forming unit assays. Exposure of NKG2D-positive AML cells to agonistic NKG2D antibody caused release of the cytokines IL-6, IL-8, IL-10 and TNF, which act as growth and survival factors for AML cells and play an important role in disease pathophysiology. NKG2D stimulation further increased engraftment of primary AML cells in NSG mice. Signaling via NKG2D was found to enhance the metabolic activity/viability of AML cells and protected the leukemic cells from treatment with the cytostatic compounds cytarabine and doxorubicin that are routinely used for AML treatment. Conclusions Taken together, our data implicate that the NKG2D/NKG2DL system, beyond its involvement in immune surveillance, may directly affect AML pathophysiology. Ongoing investigations aim to unravel the NKG2D-mediated signaling pathways, consequences of autocrine/paracrine NKG2D/NKG2DL interaction in AML cells as well as the association of NKG2D negativity with known stemness/differentiation markers and clinical disease course. Ethics Approval The study was approved by IRB (ethics committee of the Faculty of Medicine of the Eberhard Karls Universitaet Tuebingen and of the University Hospital Tuebingen) and was conducted in accordance with the Declaration of Helsinki; reference number 13/2007V. Consent Human material was collected after obtaining written informed consent of patients/participants.